Pathology of benign prostatic hyperplasia

International Journal of Impotence Research

Volumn 20, Issue SUPPL. 3, 2008, Pages

  Roehrborn, C G ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; DUTASTERIDE; EPIDERMAL GROWTH FACTOR; ESTROGEN; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 3; FINASTERIDE; KERATINOCYTE GROWTH FACTOR; TESTOSTERONE; TRANSFORMING GROWTH FACTOR;

BLADDER NECK STENOSIS; DRUG INHIBITION; HISTOPATHOLOGY; HORMONE ACTION; HUMAN; LOWER URINARY TRACT SYMPTOM; MUSCLE TISSUE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; REVIEW; SMOOTH MUSCLE; STROMA; SYMPTOM;

ANDROGENS; ANIMALS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; UROLOGIC DISEASES;

EID: 55849102788     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2008.55     Document Type: Review

References (40)

1. Roehrborn C, McConnell J. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh P, Retik A, Vaughan E, Wein A (eds). Campbell's Urology, 8th edn. Saunders: Philadelphia, 2002, pp 1297-1336.
2. Cunha GR. Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. [Review]. Cancer 1994; 74: 1030-1044.
3. McConnell JD. Prostatic growth: new insights into hormonal regulation. [Review]. Br J Urol 1995; 76(Suppl 1): 5-10.
4. Wilson JD, Roehrborn C. Long-term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts. J Clin Endocrinol Metab 1999; 84: 4324-4331.
5. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia [published erratum appears in N Engl J Med 1988; 318(9): 580]. N Engl J Med 1987; 317: 599-604.
6. Marberger M, Roehrborn CG, Marks LS, Wilson T, Rittmaster RS. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 91: 1323-1328.
7. Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004; 172(4 Pt 1): 1399-1403.
8. Martikainen P, Kyprianou N, Isaacs JT. Effect of transforming growth factor-beta on proliferation and death of rat prostatic cells. Endocrinology 1990; 127: 2963-2968.
9. Kyprianou N, Isaacs JT. 'Thymineless' death in androgen-independent prostatic cancer cells. Biochem Biophys Res Commun 1989; 165: 73-81.
10. Barrack ER, Bujnovszky P, Walsh PC. Subcellular distribution of androgen receptors in human normal, benign hyperplastic, and malignant prostatic tissues: characterization of nuclear salt-resistant receptors. Cancer Res 1983; 43: 1107-1116.
11. Rennie PS, Bruchovsky N, Goldenberg SL. Relationship of androgen receptors to the growth and regression of the prostate. Am JClin Oncol 1988; 11(Suppl 2): S13-S17.
12. Walsh PC, GM H, LL E. Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supernormal. J Clin Invest 1983; 72: 1772-1777.
13. Russell DW, Wilson JD. Steroid 5alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994; 63: 25.
14. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5 alpha reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186: 1213.
15. Carson III C, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003; 61(4 Suppl 1): 2-7.
16. Lee KL, Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J urol 2004; 172(5 Pt 1): 1784-1791.
17. Griffiths K. Molecular control of prostate growth. In: Kirby R, McConnell J, Fitzpatrick JM, Roehrborn CG, Boyle P (eds). Textbook of Benign Prostatic Hyperplasia. Isis Medical Media: Oxford, 1996, pp 23-56.
18. Story MT, Livingston B, Baeten L, Swartz SJ, Jacobs SC, Begun FP et al. Cultured human prostate-derived fibroblasts produce a factor that stimulates their growth with properties indistinguishable from basic fibroblast growth factor. Prostate 1989; 15: 355-365.
19. Lawson RK. Role of growth factors in benign prostatic hyperplasia. Eur Urol 1997; 32(Suppl 1): 22-27.
20. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol 1978; 15: 340.
21. McNeal J. Pathology of Benign Prostatic Hyperplasia. Insight into Etiology. In: Lepor H, Walsh PC (eds). The Urologic Clinics of North America, 17th edn. WB Saunders Company: Philadelphia, 1990, pp 477-486.
22. Caine MLS. The 'capsule' in benign prostatic hypertrophy. US Department of Health and Human Services 1987; No. 87-2881: 221.
23. Shapiro E, Becich MJ, Hartanto V, Lepor H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 1992; 147: 1293-1297.
24. Shapiro E, Hartanto V, Lepor H. Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color assisted image analysis. J Urol 1992; 147: 1167-1170.
25. Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004; 171: 1029-1035.
26. Lepor H, Tang R, Shapiro E. The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate 1993; 22: 301-307.
27. Lepor H, Tang R, Meretyk S, Shapiro E. Alpha1 adrenoceptor subtypes in the human prostate. J Urol 1993; 149: 640-642.
28. Uckert S, Kuthe A, Stief CG, Jonas U. Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World J Urol 2001; 19: 14-22.
29. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401-1407.
30. McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005; 47: 838-845.
31. McVary KT, Razzaq A, Lee C, Venegas MF, Rademaker A, McKenna KE. Growth of the prostate gland is facilitated by the autonomic system. Biol Reprod 1994; 51: 99-107.
32. Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol 1979; 121: 640-642.
33. Azadzoi KM, Radisavljevic ZM, Siroky MB. Effects of ischemia on tachykinin-containing nerves and neurokinin receptors in the rabbit bladder. Urology 2008; 71: 979-983.
34. Azadzoi KM, Yalla SV, Siroky MB. Oxidative stress and neurodegeneration in the ischemic overactive bladder. J Urol 2007; 178: 710-715.
35. Oishi K, Boyle P, Barry M, Farah R, Gu F-L, Jacobsen S et al. Epidemiology and natural history of benign prostatic hyperplasia. In: 4th International Consultation on Benign Prostatic Hyperplasia. Plymbridge Distributors Ltd: Plymouth, United Kingdom, 1998, pp 23-59.
36. Girman CJ. Natural history and epidemiology of benign prostatic hyperplasia: relationship among urologic measures. Urology 1998; 51(4A Suppl): 8-12.
37. Girman CJ, Epstein RS, Jacobsen SJ, Guess HA, Panser LA, Oesterling JE et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994; 44: 825-831.
38. Girman CJ, Jacobsen SJ, Guess HA, Oesterling JE, Chute CG, Panser LA et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 1995; 153: 1510-1515.
39. Girman CJ, Jacobsen SJ, Rhodes T, Guess HA, Roberts RO, Lieber MM. Association of health-related quality of life and benign prostatic enlargement. Eur Urol 1999; 35: 277-284.
40. McConnell J, Committee TMS. The long term effects of medical therapy on the progression of BPH: results from the MTOPS trial. J urol 2002; 167(4 Suppl): 265A.